Revolution Medicines
$205.89Change from previous close: +0.31%Absolute change: +$0.63
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $44.13B
- Enterprise value
- $41.38B
- Forward P/E
- -33.7
- Price/book
- 27.5
- EV/EBITDA
- -25.6
Profitability and growth
- Gross margin
- 0.0%
- Operating margin
- 0.0%
- Net margin
- 0.0%
- ROE
- -79.1%
- ROA
- -30.1%
Financial health
- Total cash
- $3.94B
- Total debt
- $1.19B
- Debt/equity
- 0.46
- Current ratio
- 11.4
- Quick ratio
- 11.1
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $257.47
- Median price target
- $257.50
- High price target
- $320.00
- Low price target
- $179.00
- Analysts with a price target
- 22
- Consensus
- Strong buy
- Forward EPS
- -$6.12
- EPS estimate, current year
- -$9.67
Shares and trading
- Beta
- 1.41
- Average volume
- 1.94M
- Shares outstanding
- 214.34M
- Float
- 184.5M
- Institutional ownership
- 101.0%
- Insider ownership
- 1.9%
- Short interest (% of float)
- 4.8%
- Short ratio (days)
- 5.53